Identifying potential prescription drug product hopping

Nat Biotechnol. 2021 Apr;39(4):414-417. doi: 10.1038/s41587-021-00877-9.

Vrushab Gowda^#^{1

2}, Reed F Beall^#^{1

3}, Aaron S Kesselheim¹, Ameet Sarpatwari⁴

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
² Harvard Law School, Cambridge, MA, USA.
³ Cummings School of Medicine and O'Brien Institute of Public Health, University of Calgary, Calgary, Alberta, Canada.
⁴ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. asarpatwari@bwh.harvard.edu.

^# Contributed equally.

No abstract available

Publication types